ICH E2A - Clinical Safety Data Management - Definitions and Standards for Expedited Reporting

What it says

ICH E2A establishes standard definitions for adverse events, adverse drug reactions, and serious and unexpected reactions occurring during clinical trials, along with expedited reporting timelines requiring serious, unexpected adverse drug reactions to be reported to regulatory authorities within specified timeframes, commonly 7 or 15 calendar days depending on severity.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Standardised definitions under this guideline are foundational to consistent safety reporting across global clinical trials, ensuring that terms like serious adverse event carry the same specific meaning regardless of which region or sponsor is reporting.
• Expedited reporting timelines create an obligation running on a similarly urgent clock to the Field Alert Report requirement discussed elsewhere in this library, though triggered by clinical trial safety findings rather than product quality information.
• This guideline connects directly to Good Clinical Practice principles under ICH E6(R3), since reliable safety data collection and reporting depends on the broader trial conduct and data integrity standards that guideline establishes.

What inspectors look for

• Whether adverse events occurring during a clinical trial are correctly classified according to the standard definitions this guideline establishes, rather than inconsistently categorised.
• Whether serious, unexpected adverse drug reactions meeting expedited reporting criteria are actually reported to regulatory authorities within the required timeframe.
• Whether the clinical trial's safety data collection and reporting processes are genuinely capable of identifying reportable events promptly, not just in theory.

Related regulations